Abstract
The primary and not yet accomplished goal remains to treat all patients with coronary heart disease to the LDL cholesterol target < 100 mg/dl. To date there is no conclusive evidence for a recommendation of a LDL cholesterol goal lower than 100 mg/dl for all patients. Patients with high vascular risk benefit from statin therapy irrespective of cholesterol levels, underlining the importance of the assessment of global vascular risk as the basis of modern lipid therapy.
MeSH terms
-
Anticholesteremic Agents / adverse effects
-
Anticholesteremic Agents / therapeutic use*
-
Cholesterol, HDL / blood
-
Cholesterol, LDL / blood*
-
Clinical Trials as Topic
-
Coronary Artery Disease / blood
-
Coronary Artery Disease / drug therapy*
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Hypercholesterolemia / blood
-
Hypercholesterolemia / drug therapy*
-
Practice Guidelines as Topic
-
Reference Values
-
Treatment Outcome
-
Triglycerides / blood
Substances
-
Anticholesteremic Agents
-
Cholesterol, HDL
-
Cholesterol, LDL
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Triglycerides